ALS

4
Pipeline Programs
8
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
TalampanelPhase 21 trial
Active Trials
NCT00696332Completed559Est. May 2010
Genentech
GenentechCA - Oceanside
1 program
1
TocilizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02469896Completed22Est. Jul 2018
Ultragenyx Pharmaceutical
1 program
1
TriheptanoinPhase 1/21 trial
Active Trials
NCT03506425Completed15Est. Mar 2019
Biogen
BiogenCAMBRIDGE, MA
2 programs
1
[11C]-PBR28Phase 11 trial
Genomic Translation for Amyotrophic Lateral Sclerosis CareN/A1 trial
Active Trials
NCT02795897Completed254Est. Jun 2022
NCT04490096Terminated2Est. Mar 2022
Providence Therapeutics
1 program
ALS/MND Natural History Study Data RepositoryN/A1 trial
Active Trials
NCT05966038RecruitingEst. Dec 2030
Clene
CleneSALT LAKE CITY, UT
1 program
CNM-Au8N/A1 trial
Active Trials
NCT06408727Available
MediciNova
MediciNovaLA JOLLA, CA
1 program
MN-166N/A1 trial
Active Trials
NCT06743776Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
GenentechTocilizumab
TevaTalampanel
Ultragenyx PharmaceuticalTriheptanoin
Biogen[11C]-PBR28
BiogenGenomic Translation for Amyotrophic Lateral Sclerosis Care
Providence TherapeuticsALS/MND Natural History Study Data Repository

Clinical Trials (8)

Total enrollment: 852 patients across 8 trials

NCT02469896GenentechTocilizumab

A Trial of Tocilizumab in ALS Subjects

Start: Nov 2015Est. completion: Jul 201822 patients
Phase 2Completed
NCT00696332TevaTalampanel

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Start: Sep 2008Est. completion: May 2010559 patients
Phase 2Completed
NCT03506425Ultragenyx PharmaceuticalTriheptanoin

A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)

Start: Jun 2018Est. completion: Mar 201915 patients
Phase 1/2Completed
NCT04490096Biogen[11C]-PBR28

Multimodal Imaging Outcome Measures for ALS (Image ALS)

Start: Feb 2021Est. completion: Mar 20222 patients
Phase 1Terminated
NCT06408727CleneCNM-Au8

Intermediate Expanded Access Protocol CNMAu8.EAP04

N/AAvailable
NCT06743776MediciNovaMN-166

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

N/AAvailable
NCT02795897BiogenGenomic Translation for Amyotrophic Lateral Sclerosis Care

Genomic Translation for Amyotrophic Lateral Sclerosis Care

Start: Jun 2016Est. completion: Jun 2022254 patients
N/ACompleted
NCT05966038Providence TherapeuticsALS/MND Natural History Study Data Repository

ALS/MND Natural History Study Data Repository

Start: Apr 2015Est. completion: Dec 2030
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 852 patients
8 companies competing in this space